Danone registered a 4.2% rise in like-for-like sales to €6.7 billion in Q2, driven by a 1.9% contribution from volume growth and a 2.3% increase from pricing.
The Paris-based firm described its performance as “solid” and illustrating the relevance of its “health-focused” portfolio.
While its performance in 2026 so far is not groundbreaking, it will offer comfort to investors at a time of considerable political and environmental uncertainty.
It has also been able to ride out the Q1 sales hit from the international infant formula recall scandal, which affected numerous manufacturers late last year and into January, including rivals Nestlé and Lactalis.
In its half-year results, Danone reported sales growth of 3.5% on a like-for-like basis to €13.9 billion, with volume increasing by 1.7%.
Overall, the company reported recurring operating income of €1.85 billion, marking an increase of 2.3% year on year.
H1 reported sales rose by 1.4%, including a positive scope effect of 0.7%, boosted by the integration of Kate Farms and the joint venture with Saputo Dairy Australia.
Danone reaffirmed its FY2026 guidance, in line with its mid-term ambitions, and expects like-for-like sales growth of between 3% and 5%, with recurring operating income growing faster than sales.
Antoine de Saint-Affrique, CEO of Danone said: “Demand for our winning platforms remained strong, including High-Protein products and Medical Nutrition across all regions, and Skyr, Kefir and Plant-based products in Europe. At the same time, we made step-by-step progress in North America EDP and saw improving trends in Infant Milk Formula in EMEA.
“While some areas still require further progress and the environment remains unstable, we enter the second half of the year with confidence that 2026 will be another year of delivery, aligned with our value creation model and mid-term ambitions.”
